Carboxypeptidase A4 (CPA4) is a member of the metallocarboxypeptidase family. A previous study indicated that CPA4 may participate in the modulation of peptide hormone activity and hormone-regulated tissue growth and differentiation. However, the role of CPA4 in lung tumorigenesis remains unclear. Our study revealed that CPA4 expression was higher in both lung cancer cells and tumor tissues. We performed 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide assays, colony-formation assays, and Cellomics ArrayScan Infinity analysis to demonstrate that CPA4 knockdown inhibited non small-cell lung cancer (NSCLC) cell proliferation.
and differentiation by modulating or inactivating peptide hormone activity resulting from the cleavage of the COOH-terminus. 4 Meanwhile, CPA4 is a maternally imprinted gene that is located in a region of chromosome 7q32 that is speculated to be associated with prostate cancer aggressiveness. [7] [8] [9] Ross et al 10 demonstrated that a nonsynonymous coding single-nucleotide polymorphism in CPA4 correlates with an increased risk of aggressive prostate cancer among younger men (<66 years). Moreover, several studies have shown that CPA4 expression is increased in multiple cancer tissues, including tissues from patients with pancreatic cancer, gastric cancer, esophageal squamous cell carcinoma, and lung cancer, and may serve as a potential diagnostic and prognostic marker. [11] [12] [13] [14] These findings suggest that CPA4 may play a crucial role in cancers; however, the role of CPA4 in lung tumorigenesis remains poorly understood.
In this study, we investigated the function of CPA4 in lung tumorigenesis. Our work revealed that CPA4 was overexpressed in most human lung cancer tissues, and decreasing CPA4 inhibited lung cancer growth by inducing apoptosis and G1-S arrest. Mechanistically, we showed that CPA4 activated the protein kinase B(AKT)/c-MYC pathway to promote lung tumorigenesis.
| MATERIALS AND METHODS

| Reagents
Roswell Park Memorial Institute 1640 medium was purchased from Thermo Fisher Scientific (Waltham, MA). F-12K medium was purchased from Sigma-Aldrich (St Louis, MO). The rabbit antibody against c-MYC was purchased from Abcam (Cambridge, UK). The rabbit antibody against CPA4 was purchased from Genetex (Irvine, CA). The rabbit antibodies against α-tubulin, β-actin, P27, cyclin-dependent kinase 4 (CDK4), B-cell lymphoma-2 (Bcl-2), caspase 9, caspase 3, p-AKT, and AKT and the mouse antibody against flag were purchased from Cell Signaling Technology (Beverly, MA). The mouse antibody against Cyclin D1 was purchased from Santa Cruz Biotechnology (Santa Cruz, MO). 
| Tissue samples and cell culture
| Quantitative real-time polymerase chain reaction
The total RNA was extracted from the tumor tissues and lung cancer cells using TRIzol reagent (Invitrogen, Carlsbad, CA). Complementary DNA was synthesized with murine leukemia virus-reverse transcriptase (Invitrogen), and each reaction was performed in triplicate using SYBR Green (Tiangen, Beijing, China) according to the manufac-turerʼs instructions using an ABI7300 real-time detection system (Applied Biosystems). Glyceraldehyde 3-phosphate dehydrogenase was used as an internal control. The program was as follows: 95°C for 2 minutes and 40 cycles of 95°C for 15 seconds, 60°C for 30 seconds and 68°C for 30 seconds. A dissociation curve was generated. The fold change in expression was calculated by the formula −ΔΔ 2 Ct . The primers used in the experiments are listed in Table S1 . The quantitative real-time polymerase chain reaction (qRT-PCR) data were calculated from triplicate reactions.
| Immunohistochemical analysis of a tissue array and mouse tumor tissues
Tissue microarrays containing 131 lung cancer tissues and corresponding nontumor tissues were purchased from Alenabio (Xi'an, China). Mouse tumor tissues were embedded in paraffin for examination. Four-micrometer-thick sections were cut and mounted on glass.
After deparaffinization and rehydration, the sections were stained with hematoxylin and eosin and analyzed by immunohistochemistry.
For the immunohistochemistry, the sections were antigen-retrieved, washed, and treated with peroxidase (Santa Cruz Biotechnology) for 5 minutes. Each slide was blocked with normal donkey serum for 20 minutes. Then, the slides were incubated with an anti-CPA4 antibody (1:100; Abcam), and mouse tumor tissues were incubated with an anti-Ki67 antibody (1:100; Abcam). After washing twice with phosphate-buffered saline (PBS), the slides were hybridized with a secondary antibody, followed by incubation with a peroxidasestreptavidin reagent. Then, the color was developed using a diaminobenzidine substrate, and the sections were counterstained with hematoxylin. The results were assessed by two independent pathologists. The following criteria were used to quantify the protein expression level of CPA4: the CPA4 staining intensity was classified as no (score = 0), weak (score = 1), moderate (score = 2), or strong (score = 3) staining; and the positive percentage of CPA4 cells was scaled as 0% (score = 0), 1% to 25% (score = 1), 26% to 50% (score = 2), 51% to 75% (score = 3), or 76% to 100% (score = 4). The values of the staining intensity were multiplied by the percentage to obtain a single CPA4 score for each sample. The mean score of tumors vs adjacent tissues was compared by the Student t test (two-tailed). 
|
| Colony-formation assay
Cells were seed into six-well plates at 1000 cells/well and cultured for 10 days. At the assay endpoint, the cells were washed gently with PBS, fixed with prechilled methanol for 10 minutes and stained with crystal violet for 15 minutes. Stained colonies with more than 50 cells were considered colony-forming units. The experiment was performed in triplicate wells in three independent experiments. 
| Apoptosis analysis
| Cell cycle analysis
Flow cytometry was used to analyze the cell cycle according to the manufacturerʼs instructions. After a 96-hour transduction with shRNAs, the cells were subjected to cell cycle analysis. Briefly, cells
(1 × 10 6 ) were harvested by centrifugation at 700 rpm for 5 minutes.
Then, cells were washed twice with PBS and fixed with ice-cold 70% ethanol overnight at 4°C. The cell pellets were washed with PBS, followed by resuspension in 500 mL of PBS containing 50 mg/mL propidium iodide, 0.1 mg/mL RNase A, and 0.05% Triton X-100, and incubated for 15 minutes in the dark at 4°C. Cell cycle distribution was determined using a flow cytometer (Millipore, Boston, MA). The experiment was performed in triplicate.
| Cellomics ArrayScan infinity
Cell proliferation was evaluated using a Cellomics ArrayScan Infinity system (Nexcelom, MA) to quantify the number of fluorescent cells.
Cells were infected with the lentiviral particles for 72 hours. Then, cells were seeded into 96-well plates at 2000 cells/well in triplicates and assessed for the indicated durations. 
| Western blot analysis
| Lentivirus transduction
The GV143-CPA4-flag plasmid and GV115-CPA4 shRNA were purchased from GeneChem (Shanghai, China). The transduction assay was performed according to the manufacturerʼs protocols.
The specific sequences of shRNAs were as follows: shCPA4 1#: 5′-GT ATGACAACGGCATCAAA-3′; shCPA4 2#: 5′-ACCGGCCGATGTA TGTACTCCACGAGAUGGACAACAUUTT-3′. Cells were infected with the lentiviral particles for 72 to 96 hours, and the cells were then subjected to qRT-PCR analysis, flow cytometry analysis, cell proliferation assays, and Western blot analysis with the indicated antibodies.
| Affymetrix gene expression array
Affymetrix gene expression assays were performed according to the manufacturerʼs protocols (Affymetrix Inc, San Francisco, CA). In brief, the quality control of total RNA from cells was performed with an Agilent 2100 instrument. Amplified RNA was obtained using a 
| Statistical analysis
All data are shown as the mean ± SD. Unless stated otherwise, statistical analyses were conducted using the Student t test.
Significance was defined as P < .05.
3 | RESULTS
| CPA4 is upregulated in human lung cancer cells and primary tumors, and its expression is associated with poor prognosis
We first examined CPA4 expression in lung cancer cells and lung normal epithelial cells. The result showed that CPA4 protein level was significantly overexpressed in lung cancer cells compared with that in lung normal epithelial cell Beas-2B ( Figure 1A ). Then, we performed qRT-PCR to evaluate CPA4 gene expression in 20 tumor tissues and corresponding nontumor tissues. We found that CPA4
mRNA was significantly upregulated in 14 tumor tissues ( Figure 1B ).
To confirm this result, we expanded the number of lung cancer tissues to evaluate CPA4 protein expression by immunohistochemistry. We multiplied the staining intensity by the percentage to obtain a score for the quantification of CPA4 protein expression. The results showed that CPA4 was increased in 93 of the 131 (71%) tumor tissues compared with that in the adjacent tissues ( Figure 1C and 1D). Meanwhile, we analyzed TCGA datasets for CPA4 expression.
The results indicated that CPA4 expression was higher in NSCLC tissues compared with that in normal tissues ( Figure 1E ). Further, the Kaplan-Meier survival curve showed that high CPA4 expression was correlated with poor prognosis ( Figure 1F ). These results indicate that CPA4 may serve as a novel diagnostic marker of NSCLC.
| CPA4 promotes lung cancer cell growth
To explore the function of CPA4 in lung cancer, we generated CPA4 knockdown cells by transducing CPA4 shRNAs into H1299 and A549 cells. The effects of CPA4 knockdown were confirmed by both qRT-PCR and Western blot analysis (Figure 2A and 2B ).
Colony-formation assays revealed that CPA4 depletion (shCPA4) dramatically reduced the clonogenicity of lung cancer cells compared with nontargeted (shCtrl) cells ( Figure 2C ). In contrast, CPA4 overexpression in A549 cells markedly enhanced the clonogenic ability compared with vector control cells ( Figure 2D and 2E). Moreover, MTT assays showed that CPA4 downregulation resulted in a significant decrease in cell proliferation compared with that in nontargeted cells in both H1299 and A549 cells ( Figure 3A) . We further performed proliferation analysis with Cellomics ArrayScan Infinity in H1299 and A549 cells. Similarly, the results indicated that decreased CPA4 led to an inhibition of lung cancer cell growth ( Figure 3B ). Taken together, these results indicate that CPA4 promotes lung cancer cells growth.
| Knockdown of CPA4 induces G1-S arrest and apoptosis
To investigate the mechanism by which CPA4 enhances cell growth, we performed a genome-wide analysis of gene expression changes following CPA4 knockdown in H1299 cells. The results showed that CPA4 expression was significantly decreased (−1.64-fold change; | 2031 P = .002) in the CPA4 knockdown cells compared with shCtrl cells (data not shown). Using an absolute fold change of at least 2.0 and P < .05, we identified 360 upregulated genes and 460 downregulated genes in the knockdown cells compared with shCtrl cells ( Figure 4A ; Table S2 ). Then, we performed functional classification based on 820 genes whose expression levels were altered upon CPA4 knockdown using ingenuity pathway analysis. The results showed that these differentially expressed genes were enriched in various biological functions, including cellular growth, cell cycle, cell death, and cellular development ( Figure 4B and 4C) . Considering the pivotal role of cell cycle distribution and apoptosis in cell growth, we assessed the effect of CPA4 on cell cycle and apoptosis by flow cytometry. Loss of CPA4 in H1299 cells led to a 20.1% increase in G1 phase and 13.8% and 6.3% decreases in S and G2 phases, respectively. In A549 cells, CPA4
knockdown resulted in an 8.2% increase in the G1 phase and a concomitant decrease in G2 phase ( Figure 5A and 5B ). In agreement with this result, CPA4 downregulation reduced the expression of Cyclin D1 and CDK4 and elevated the expression of P27 ( Figure 5C ).
Furthermore, CPA4 knockdown elicited a significant increase in the number of apoptotic H1299 cells (9.65 ± 0.67% vs 4.53 ± 0.35%; P < .001) and A549 cells (8.77 ± 0.61% vs 4.85 ± 0.6%; P < .001) compared with shCtrl cells (Figure 5D and 5E). Concurrently, CPA4
knockdown cells exhibited a decrease of antiapoptosis protein Bcl-2
and an increase of proapoptosis protein cleaved-caspase 9 and cleaved-caspase 3 compared with shCtrl cells ( Figure 5F ). Together, these results indicate that CPA4 knockdown inhibits lung cancer cells growth by inducing G1-S arrest and cell apoptosis.
| CPA4 promotes lung cancer cells growth via the AKT/c-MYC pathway
To explore the molecular mechanism involved in the regulation of induced by CPA4 overexpression (Figure 6D) . Thus, c-MYC is required for CPA4 to promote lung cancer cell growth. Further, we sought to explore how CPA4 regulates c-MYC. Studies have reported that the transcription of c-MYC can be induced via AKT pathway. 17, 18 In addition, MCP subfamily carboxypeptidase E (CPE) has been shown to increase the phosphorylation of AKT. 19 Thus, we examined whether CPA4 affected the phosphorylation of AKT. The result showed that CPA4 depletion impaired AKT phosphorylation ( Figure 6B ). Conversely, CPA4 overexpression increased the protein levels of phosphorylated-AKT ( Figure 6C ).
Taken together, these results suggest that CPA4 enhances lung cancer growth via the AKT/c-MYC pathway.
| Knockdown of CPA4 inhibits subcutaneous tumor growth in nude mice
To evaluate the suppressive effect of CPA4 on lung tumor growth in vivo, we generated xenograft tumor models by subcutaneously injecting H1299-shCPA4 1# and H1299-shCtrl cells into nude mice. The result showed that CPA4 knockdown inhibited tumor growth in nude mice ( Figure 7A ). The weight and volume of tumors derived from H1299-shCPA4 1# cells were significantly reduced compared with H1299-shCtrl cells ( Figure 7B and 7C ). Further, we assessed the protein levels of p-AKT and c-MYC in tumor xenograft tissues. In accordance with our above results, Western Differentially expressed genes were grouped and statistically analyzed using IPA. C, Heatmap showing the functional classification of CPA4-regulated genes. Differentially expressed genes were grouped and statistically analyzed using IPA. Orange represents a Z score >2; blue represents a Z score <−2; white represents a Z score = 0; gray represents no Z score; Z score >2 indicates that differentially expressed genes activate this function; Z score <−2 indicates that differentially expressed genes inhibit this function. CPA4, carboxypeptidase A4; IPA, ingenuity pathway analysis [Color figure can be viewed at wileyonlinelibrary.com] Figure 7D ). In addition, fewer proliferative cells were detected in the tumors derived from H1299-shCPA4 1# cells than that derived form H1299-shCtrl cells by Ki67 staining ( Figure 7E ). TUNEL assay results showed a higher level of cell apoptosis in CPA4 knockdown tumor tissues ( Figure 7E ). Overall, these data indicated that downregulation of CPA4 inhibits lung cancer growth in vivo.
| DISCUSSION
The MCP family is classified as CP A/B and CP N/E according to the amino acid sequence similarities and overall domain structure. 5 CPA4 belongs to the CP A/B subfamily and shares 54% and 63% homology with CPA1 and CPA2, respectively. 20 MCP has been reported to be linked to tumorigenesis. CPA7 elicited an inhibitory effect on prostate cancer growth by suppressing STAT3 signaling. 21 Wnt/β-catenin pathway. 22 However, whether CPA4 functions in tumorigenesis is still unknown. In this study, we demonstrated that CPA4 depletion suppressed lung cancer growth in vitro and in vivo.
Mechanistically, CPA4 knockdown decreased the expression of c-MYC through the AKT pathway, thus inducing G1-S arrest and cell apoptosis.
Our work indicates that CPA4 plays an oncogenic role in lung cancer.
We identified that CPA4 expression was increased in lung cancer cells and most tumor tissues. This finding is consistent with previous reports that CPA4 was overexpressed in NSCLC, gastric cancer, and pancreatic cancer. 11, 12, 14 19 These results suggest that CPA4 promotes lung cancer growth though promoting cell proliferation and inhibiting cell apoptosis.
We also explored how CPA4 regulates lung cancer cell proliferation and apoptosis. The gene expression profiles suggested that c-MYC was a potential candidate target controlled by CPA4. c-MYC is a transcription factor that is overexpressed in many malignancies.
The aberrant expression of c-MYC promotes tumorigenesis by accelerating cell cycle progression and inhibiting cell apoptosis. [23] [24] [25] Our results showed that CPA4 downregulation reduced the expression of c-MYC. Knockdown of c-MYC in CPA4-overexpressing cells blocked the increase of Bcl-2 and restored the expression of P27,
indicating that c-MYC may be the cause of CPA4 promoting lung cancer growth. In accordance with our findings, N-terminally truncated CPE has been reported to induce c-MYC expression to promote osteosarcoma cells migration and invasion. 22 Thus, these results indicated that CPA4 promotes NSCLC growth via c-MYC.
We further found that CPA4 knockdown impaired AKT phosphorylation. The AKT pathway participates in multiple cellular processes, including cell proliferation, apoptosis, and cell cycle. Studies have reported that activation of AKT pathway promotes tumorigenicity of breast cancer cells and survival of lymphoid cells via the upregulation of c-MYC. 17, 18 In addition, the cooperation of activated AKT and c-MYC induces cell proliferation and transformation. 26 Our study found that CPA4 promoted cell cycle progression and inhibited cell apoptosis though the AKT/c-MYC pathway. The activation of AKT pathway is generally considered to be controlled by phosphatidylinositol 3-kinase (PI3K) and epidermal growth factor receptor (EGFR) activation. 27 We first performed Western blot analysis to examine whether CPA4 can alter the phosphorylation of EGFR. The result indicated that CPA4 did not affect EGFR activity (data not shown). PI3K is a lipid kinase that comprises of a p85 regulatory subunit and a p110 catalytic subunit.
Activation of p85 relieves the inhibition of p110 by p85 and activates the AKT pathway. 28 Meanwhile, Cheng et at 19 reported that MCP subfamily of CPE inhibited H 2 O 2 -induced cell apoptosis through the PI3K/AKT pathway. On the basis of these findings, we propose that CPA4 may be secreted to extracellular domain as an extracellular stimulus to activate p85, thereby enhancing the AKT activity. This hypothesis is still being explored.
Collectively, we found a novel gene in lung cancer that was overexpressed in tumor tissues. We demonstrated that CPA4 knockdown suppressed lung cancer growth in vitro and in vivo.
Suppressing CPA4 expression induced G1-S arrest and cell apoptosis by inhibiting the AKT/c-MYC pathway. These results indicate that CPA4 may be a potential target for the treatment of NSCLC.
| CONCLUSION
In summary, our work showed that CPA4 downregulation inhibits lung tumorigenesis by regulating the AKT/c-MYC pathway. This finding might serve as a basis for the treatment of NSCLC.
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